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The WHO recommends the administration of sulfadoxine-pyrimethamine (SP) to all pregnant
women living in areas of moderate (stable) to high malaria transmission during scheduled
antenatal visits, beginning in the second trimester and continuing to delivery. Malaria
parasites have lost sensitivity to SP in many endemic areas, prompting the investigation of
alternatives that include azithromycin-based combination (ABC) therapies. Use of ABC
therapies may also confer protection against curable sexually transmitted infections and
reproductive tract infections (STIs/RTIs). The magnitude of protection at the population level
would depend on the efficacy of the azithromycin-based regimen used and the underlying
prevalence of curable STIs/RTIs among pregnant women who receive preventive treatment.
This systematic review summarizes the efficacy data of azithromycin against curable STIs/RTIs.
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The WHO recommends the administration of
sulfadoxine-pyrimethamine (SP) to all pregnant
women who live in areas of moderate (stable)
to high malaria transmission during scheduled
antenatal care (ANC) visits, beginning in the
second trimester and continuing to delivery [1].
This intervention, known as intermittent pre-
ventive treatment of malaria in pregnancy
(IPTp), is national policy in 36 countries
worldwide, 35 of which are in sub-Saharan
Africa [2]. The objective of IPTp-SP is to reduce
the incidence of low birthweight and maternal
anemia attributable to malaria. In recent years,
however, malaria parasites have developed resist-
ance to SP such that IPTp no longer reduces
the incidence of low birthweight in some epide-
miological settings, particularly in East Africa [3].
Evidence suggests that in areas where parasites
express the 581G dhps mutation that is associ-
ated with SP resistance, the administration of
IPTp-SP may even harm fetal growth [4–6].
Thus, the urgency to replace SP has never been
greater and azithromycin-based combination
(ABC) therapies are among leading candidates
to do so.
Azithromycin is a slow-acting analog of
erythromycin in the macrolide (azalide) class
of drugs, which targets the ribosomal subunit
of susceptible microorganisms and causes cellu-
lar death by inhibiting protein synthesis [7]. It
has in vitro and in vivo antimalarial proper-
ties [8] and can be safely administered during
pregnancy [9]. Two human challenge studies
have published results of azithromycin mono-
therapy treatment against Plasmodium falcipa-
rum infection. The first study reported a
protective effect of 40% (n = 10; 95% CI:
12–74%) among immunologically naı¨ve
patients who received 250 mg azithromycin
daily for 2 weeks prior to inoculation and for
1 week more following exposure [10]. When
the same regimen was used for one additional
week post-inoculation, treatment efficacy was
100% (n = 10) [11]. Despite this finding, com-
parable results have not been replicated in
endemic settings where patients often have
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mixed and multiple infections. However, in vitro evidence sug-
gests that azithromycin may be combined with antimalarial
partner drugs to prevent or to cure P. falciparum infection [12],
the malaria species most prevalent in sub-Saharan Africa and
which uniquely adhere to the placenta of pregnant women. In
addition to reducing the burden of malaria infection, ABC
therapies may also protect against adverse birth outcomes
attributable to curable sexually transmitted and reproductive
tract infections (STIs/RTIs). This could offer considerable pub-
lic health impact. A recent meta-analysis suggests that curable
STIs/RTIs are as prevalent as malaria parasitemia, if not more
so, among pregnant women who attend ANC facilities in sub-
Saharan Africa [13]. Five curable STIs/RTIs – Treponema pal-
lidum, Neisseria gonorrheae, Chlamydia trachomatis, Trichomonas
vaginalis and bacterial vaginosis – are associated with adverse
birth outcomes that include spontaneous abortion [14–18],
stillbirth [19–21], intrauterine growth retardation [20,22,23], prema-
ture rupture of membranes [24–26], preterm birth [17,22,23,26–33]
and low birthweight (TABLE 1) [20,23,24,28,29,33–35]. This paper sum-
marizes azithromycin efficacy and sensitivity against these cura-
ble STIs/RTIs and highlights important issues for policymakers
to consider while determining the potential use of ABC thera-
pies in IPTp.
Methodology
Between April and May 2013, PubMed, MEDLINE and
EMBASE were searched using Medical Subject Headings and
free-text terms for publications specific to the curable STIs/
RTIs noted above. With each query, the infection and causal
organism were used together, for example, ‘Syphilis’ AND
‘Treponema pallidum’, and then combined with search terms
‘azithromycin’ OR ‘macrolide’. Because the evidence base is
limited with respect to azithromycin and some curable STIs/
RTIs, both ‘azithromycin’ and ‘macrolide’ were used as filters.
We had particular interest in randomized clinical trials (RCTs)
that compared azithromycin against the current first-line treat-
ments for curable STIs/RTIs in pregnancy, noting that azithro-
mycin is the WHO-recommended treatment for pregnant
women infected with C. trachomatis. Searches were limited to
the English language and strict inclusion and exclusion criteria
were applied so as to narrow the number of papers retained.
Reference lists were also reviewed for additional documents.
Excluded records and full-text articles were in seven categories:
• ‘Unrelated outcomes’ were studies that reported nonclinical
aspects of azithromycin use such as cost-effective analysis,
noncommunicable diseases such as heart disease or pharma-
cological outcomes involving a route of administration that is
not applicable to this review (e.g., intravenous);
• ‘Unrelated organisms’ were papers dedicated to microbes
that are not the focus of this review;
• ‘Not specific to STI/RTI’ were articles on the subject of
same genus of interest, for example, Chlamydia, but were not
specific to the genital tract, for example, Chlamydia
pneumoniae;
• ‘Not related to azithromycin or close macrolide family’
were papers that did not contain macrolides in their analysis
or outcomes, but focused on different antimicrobials against
the organisms in question;
• ‘Sequential observations from same source’ involved sur-
veillance reports from which most recent data set was used;
• ‘General discussion papers’ contained information pertinent
to the search, but failed to provide specific data for STIs/
RTIs.
• ‘Contraindicated in pregnancy’ were papers that reported
outcomes of azithromycin combined with antimicrobial com-
pounds that are considered unsafe in pregnancy.
A total of 122 articles met our primary inclusion criteria
(FIGURE 1).
Results
Treponema pallidum
In vivo evidence
The WHO recommends treating pregnant women with syphilis
infection using 2.4 million units of benzanthine penicillin G
(BPG) administered by intramuscular injection [36]. Thus, we sum-
marize the results of the six clinical trials that reported outcomes
among nonpregnant adults following treatment with BPG, azithro-
mycin or a combination of BPG and azithromycin (TABLE 2). The
oldest data are from a trial in the USA (1993–1997) in which
individuals who discovered they had been exposed to infectious
stage syphilis through sexual intercourse in the preceding 30 days
were given either 1 g azithromycin (n = 40) or BPG (n = 23).
Three months post-treatment, rapid plasma reagin (RPR) and flu-
orescent treponemal antibody absorption tests (FTA-ABS) were
negative for all participants in both treatment groups [37]. Another
trial in the USA during the same time period was designed to
measure treatment outcomes in a population at high risk of con-
tracting STIs/RTIs. Although diagnostic methods were not
reported, the trial was suspended after two of the first 12 patients
were provided 1 g azithromycin failed their test of cure while all
13 participants were cured using BPG (p = 0.18) [38]. A three-arm
trial of early syphilis in the USA then compared treatment out-
comes among patients given BPG, or 2 g azithromycin once or
2 g azithromycin two-times with 1 week in between doses. RPR
and FTA-ABS testing showed that cure was achieved in 85.7%
(n = 14; 95% CI: 60.0–95.7%) of patients given BPG, 94.1%
(n = 17; 95% CI: 72.7–98.6%) among recipients of 2 g
azithromycin once and 82.8% (n = 29; 95% CI: 65.3–92.3%) in
participants who twice received 2 g azithromycin [39].
In sub-Saharan Africa, three trials have investigated BPG ver-
sus azithromycin, the first being a community-randomized trial
in Uganda (1994–1998) among nonpregnant adults with sero-
logical syphilis. Diagnosis and test of cure were based on tolui-
dine red unheated serum tests (TRUSTs) and Treponema
pallidum hemagglutination assays. Treatment efficacy varied
across regimens depending on TRUST titers at enrolment.
Among patients with initial titers <1:2, BPG cured 71.0%
(n = 93; 95% CI: 61.0–79.2%) of cases compared with 58.5%
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(n = 94; 95% CI: 48.4–68.0%) among recipients of 1 g azi-
thromycin and 70.6% (n = 313; 95% CI: 65.3–75.4%) of par-
ticipants given 1 g azithromycin plus BPG. If titers at
enrolment were >1:4, the efficacy of BPG was reduced to
41.3% (n = 75; 95% CI: 30.9–52.7%). Treatment efficacy was
also lower among groups given azithromycin but higher than
BPG alone. Recipients of 1 g azithromycin alone had a cure
rate of 53.3% (n = 71; 95% CI: 42.0–64.7%), whereas 1 g azi-
thromycin plus BPG cured 54.7% of cases (n = 309; 95% CI:
49.1–60.2%) [40].
These results were followed by a trial carried out in Tanza-
nia (2000–2003) among patients who were recruited by screen-
ing high-risk populations. All 328 subjects had a titer of at
least 1:8 on RPR test; 106 had baseline titers of >1:64, levels
indicative of active syphilitic lesions. Confirmed by RPR test
and T. pallidum particle agglutination assay, serological cure
was observed in 97.5% (n = 163; 95% CI: 93.9–99.0%) of
participants given 2 g azithromycin versus 95.2% (n = 165;
95% CI: 90.7–97.5%) in the BPG group [41].
The most recent study comparing the efficacy of azithromy-
cin versus BPG is a multicenter trial (2000–2007) in Madagas-
car (n = 421) and North America (n = 94) among HIV-
negative patients with early syphilis. Based on RPR testing,
serological cure was reported in 77.6% of subjects given 2 g
azithromycin (n = 232; 95% CI: 71.8–82.5%) and 78.5%
(n = 237; 95% CI: 72.8–83.3%) in the BPG group. Nonseri-
ous adverse events were reported by 61.5% (n = 174; 95% CI:
55.7–67.0%) of individuals treated with 2 g azithromycin,
most of whom had self-limiting gastrointestinal discomfort,
whereas 46.1% (95% CI: 40.6–52.1%) of BPG recipients
reported nonserious adverse events [42].
In vitro evidence
Fourteen in vitro studies met our inclusion criteria, seven with
isolates from low-risk populations (TABLE 3) and seven from high-
risk or mixed-risk groups (TABLE 4). A report from San Francisco
in 2001 was the first to associate azithromycin treatment failure
with A!G mutations at the 2,058 position of the 23S rRNA
gene of T. pallidum [43]. Retrospective analysis of samples
revealed that 4.0% (n = 25; 95% CI: 0.9–19.6%) of isolates
had A!G mutations between 1999 and 2002. In 2003, the
proportion of isolates with A!G mutations increased to
36.7% (n = 30; 95% CI: 21.9–54.6%) [44]; by 2004, 56.1%
(n = 66; 95% CI: 44.0–67.3%) had selected for resistance [43].
However, in Dublin, 88.2% (n = 17; 95% CI: 65.3–96.4%)
of isolates already had A!G mutations by 2002 [44].
Macrolide resistance is strongly associated with use by an
individual in the previous year. Isolates from Seattle (2001–
2005) were two-times more likely to be resistant if patients had
been treated with macrolides in the past 12 months (RR: 2.2;
95% CI: 1.1–4.4; p = 0.02) [45]. This relationship persisted
over the decade. A2058G and A2059G mutations, which are
associated with clinical failures of azithromycin, were found in
88.9% (n = 36; 95% CI: 74.6–95.5%) of isolates from 2001 to
2010 among patients exposed to macrolides in the precedingT
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12 months, whereas 61.2% (n = 98; 95% CI: 51.3–70.4%) of
isolates from patients who had not received prior macrolide
treatment contained the same mutations [46]. Similar mutations
were found among strains of T. pallidum in eight cities across
China (2008–2011). A2058G was present in 97.0% individuals
who had taken macrolides in the previous 12 months versus
62.5% of patients who had not (n = 211; OR: 19.65; 95% CI:
5.8–66.9) [47]. The opposite was found in Taiwan (2009–2011)
where no single A2058G or A2059G mutation was seen among
211 isolates tested from a population where only one person
had been given macrolide therapy in the previous year [48]. Sim-
ilarly, there was no evidence of resistance among 141 amplified
samples from HIV-negative heterosexual patients in Madagas-
car [49]. Although use of macrolides in the previous year was not
reported, the Essential Drugs List of the Malagasy Ministry of
Health does not include macrolides [301].
Neisseria gonorrhoeae
In vivo evidence
The WHO recommends treating pregnant women with Neisse-
ria gonorrhoeae infection using 400 mg cefixime as a single dose
or 125 mg ceftriaxone by intramuscular
injection [50]. However, azithromycin has
been used for the treatment of gonor-
rhea among nonpregnant adults during
the past two decades. Eleven trials were
identified through our review (TABLE 5).
Nine trials conducted between the late
1980s and 1999 investigated the use of
1 g azithromycin among individuals
attending sexually transmitted infection
(STI) clinics. Of these, three were open
label without comparators [51–53] and six
were two-arm trials that compared azi-
thromycin to ciprofloxacin and/or
doxycycline [54–59]. The pooled efficacy
of azithromycin against N. gonorrhoea,
estimated using random effects mod-
els [60], was 97.0% (n = 539; 95% CI:
95.5–98.5%). This is slightly higher
than 96.5% (n = 539; 95% CI: 94.3%–
97.6%) reported in a 2010 review [61]
that added numerators and divided the
sum of denominators among the same
nine trials. Such an approach does not
account for heterogeneity across study
populations and gives equal weight to all
trials regardless of their precision.
Regardless of pooling methods, it is
unlikely that the same efficacy would be
observed today using 1 g azithromycin
in high-income countries following
25 years of cumulative drug pressure.
However, the epidemiological context in
sub-Saharan Africa is likely different
where azithromycin use has been almost exclusively limited to
trachoma eradication campaigns [62].
We identified two RCTs that investigated the use of 2 g azi-
thromycin among patients at STI clinics. The first was a multi-
center trial in the USA (1991–1992) in which 98.9%
(n = 374; 95% CI: 97.3–99.6%) of patients were cured [63].
A similar RCT in New Delhi (2005–2006) involved 42 partici-
pants; loss to follow-up was high, 52.4%, but all 22 subjects
who returned for a test of cure had their N. gonorrhoeae infec-
tions cured [64].
In vitro evidence
Over the past decade, in vitro studies have documented the loss
of N. gonorrhoeae sensitivity to azithromycin. There are no
standard breakpoints of minimum inhibitory concentrations
(MICs) used to categorize N. gonorrhoeae resistance to azithro-
mycin, but >1 mg/ml [65] and >2 mg/ml [66] have both been
used. In this section, we summarize the key regional observa-
tions from 36 in vitro studies (TABLES 6 & 7).
The Public Health Agency of Canada reported that 0.17%
(n = 40,875; 95% CI: 0.001–0.002%) of N. gonorrhoeae
7,491 records identified
from database searches
11 records identified 
from other sources
2,095 duplicate records
159 records in ineligible language
5,248 records screened
3,972 records excluded
 2,428 Unrelated outcomes
 335 Unrelated organisms
 854 Not specific to STI/RTI
 355 Not related to azithromycin or
  close macrolide
1,276 full-text articles
reviewed
1,154 articles excluded
 599 Unrelated outcomes
 49 Unrelated organisms
 46 Not specific to STI/RTI
 233 Not related to azithromycin or close macrolide
 6 Sequential observations from same source†
 219 Discussion papers
      2 Contraindicated combinations
122 articles included in
systematic review
Figure 1. Identification, screening and eligibility of studies included in
systematic review.
†Surveillance reports from which the most recent data set was used.
STI/RTI: Sexually transmitted infection and reproductive tract infection.
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samples were resistant to azithromycin between 2000 and 2009,
although the modal value of the MIC shifted from 0.25 mg/ml
in 2001 to 0.5 mg/ml between 2007 and 2009 [67]. During the
same 10-year period, the Centers for Disease Control and Pre-
vention in the USA reported that 0.04% (n = 87.566; 95% CI:
0.03–0.06%) of N. gonorrhoeae isolates tested had MICs
‡8 mg/ml (including 25 with 8 mg/ml and 14 with 16 mg/
ml) [68]. This did not include five cases of azithromycin-
resistant N. gonorrhoeae found between August and October
2009 among men who have sex with men; three had MICs of
8 mg/ml and two had 16 mg/ml [69]. Resistance may have
appeared in Europe slightly before North America. Analysis of
isolates from 17 European countries found that 3.2% (n = 836;
95% CI: 0.02–0.05%) of gonococcal isolates were resistant to
azithromycin in 2006. By 2007, 6.8% (n = 973; 95% CI:
0.05–0.09) of samples were resistant. The overall proportion of
resistant isolates declined in 2008 to 1.8% (n = 940; 95% CI:
0.01–0.03%), although only 5.2% (95% CI: 4.1–6.8%) of
strains tested in the same year were fully susceptible to azithro-
mycin and ciprofloxacin. Four isolates from Scotland and one
from Ireland exhibited MICs >256 mg/l [68].
Gonococcal isolates examined from South America and
Cuba exhibited high but stable levels of resistance between
2000 and 2009 in most settings [70]. Collectively, azithromycin
resistance was 13.0% (n = 8,373; 95% CI: 12.3–13.7%) based
on data from six countries including Chile, an outlier.
Table 7. Sensitivity testing of N. gonorrhoeae isolates to azithromycin.
Study (year) Country Year(s) Sample
size
MIC range
(mg/ml)
Percent of
strains
susceptible
Additional details Ref.
High-risk populations
CDC (2011) USA 2009 55 NR 90.9% 9.1% resistant (95% CI: 4.0 to
19.6%); of 5 resistant (all from
MSM), 3 had MIC = 8 mg/ml
and two had MIC = 16ug/ml
[69]
Starnino et al. (2009) Italy 2007–2008 219 1.0–256.0 90.0% 72.7% (95% CI: 51.6–86.8%)
of resistant isolates from MSM
[176]
Donegan et al. (2004) Bali 2004 147 0.013–0.512 100% Study in FSWs; prevalence of NG
estimated to be 35-60%
[177]
Morris et al. (2009) USA 2000–2002 79 0.03–0.5 100% Increased MIC values seen in
MSM subject isolates
[178]
Leven et al. (2003) Indonesia 1996 267 0.032–0.5 100% Study in FSWs; prevalence of NG
estimated to be 18–44%
[179]
CDC (2000) USA 1999 12 1.0–4.0 NR Median MIC was 2.0 mg/ml. 6 of
12 samples were from men who
had sex with a CSW; 2 of
12 were from HIV positive men
[180]
Mixed-risk populations
Bruck et al. (2012) UK 2005–2006 147 NR 99.3% Mixed male heterosexual, MSM
and female heterosexual isolates
[181]
Dan et al. (2010) Israel 2002–2007 406 0.023–8.0 91.8% Mixed male heterosexual, MSM
and female heterosexual;
resistance to azithromycin did
not appear to rise over 5 year
period
[182]
McLean et al. (2004) USA 1999–2001 1,248 £4 97.4% Mixed high- and low-risk
population. Median MIC was
2.0ug.mL
[183]
Arreaza et al. (2003) Spain 1992–2001 63 0.03–4.0 96.8% 58.7% of strains had reduced
susceptibility (0.25–1.0 mg/ml).
50% of resistant isolates were
from FSW
[184]
BV: Bacterial vaginosis; CSW: Commercial sex worker (gender not specified); FSWs: Female sex workers; GI: Gastrointestinal; MIC: Minimum inhibitory concentration;
MSM: Men who have sex with men; NG: Neisseria gonorrhoeae; NR: Not reported; PROM: Preterm premature rupture of the membranes; SD: Standard deviation;
TOC: Test of cure.
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Averaged over the decade, 26.7% (n = 3,116; 95% CI 25.2–
28.3%) of samples from Chile were resistant, rising to 45.6%
(n = 463; 95% CI: 41.1–50.1%) according to the most recent
data from 2009. Removing Chile from the regional summary,
4.4% (n = 5,257; 95% CI: 3.9–5.1%) of isolates were resistant
over the decade.
All 60 gonococcal isolates from India between 2004 and
2005 were susceptible to azithromycin [71]. Pooled analysis of
samples collected from India, Pakistan and Bhutan between
2007 and 2011 found that 76.9% (n = 65; 95% CI:
65.3–85.5%) were susceptible. Results were not stratified by
country and, therefore, it is not known whether the sensitiv-
ity of isolates from India had changed [72]. Applying the
more conservative breakpoint of >1 mg/ml to the in vitro
studies identified in this review, 35% (7 of 20) of the
in vitro studies reported upper range MICs that included
gonococcal isolates resistant to azithromycin. This percentage
does not include 16 studies we identified and included
in TABLES 6 & 7 that did not report MICs.
Chlamydia trachomatis
In vivo evidence
The WHO recommends treating pregnant women with Chlamy-
dia trachomatis infection using 1 g azithromycin as a single oral
dose [50]. We found eight RCTs in the literature that reported
the treatment efficacy of 1 g azithromycin among pregnant
women (TABLE 8) [73–80]. Using random effect models, we estimate
the pooled treatment efficacy to be 92.1% (n = 268; 95% CI:
88.4–95.7%). The estimated efficacy would be higher if we
excluded two trials that were conducted in the USA. The first
trial (1995–1997) reported a 3-week test of cure rate to be
88.1% (n = 42; 95% CI: 74.9–94.7%) [76], whereas the second
trial (1998–2000) was terminated early due to poor efficacy,
63.3% (n = 55; 95% CI: 50.4–75.1%), based on test of cure
‡4 weeks post-treatment [74]. These results need to be interpreted
with caution because no distinction was made between treatment
failures and new infections, sex partners were not treated by trial
staff, but were referred to a treatment center, and only 35% of
women were seen within 7 days of the scheduled test of cure.
Studies investigating sexual activity following treatment offer
some perspectives on post-treatment infections and the extent
to which they may be failures or de novo infections. A trial in
Seattle (1998–2003) found that persistent or recurrent chlamy-
dial or gonorrheal infection occurred in 7.6% (n = 289; 95%
CI: 5.1–4.9%) of female patients who reported no sexual inter-
course after treatment [81]. Another study reported that 19.0%
(n = 79; 95% CI 11.9–29.0%) of women were positive for C.
trachomatis 3 months after treatment using 1 g azithromycin.
Of these women, 13.3% (n = 15; 95% CI: 4.0–38.3%)
reported being sexually inactive during the post-treatment
period [82]. These findings may be attributable to false reporting
of sexual contact, or treatment failure or may lend credence to
the hypothesis that C. trachomatis enters a latent asymptomatic
state that is undetectable by culture or, possibly, Nucleic Acid
Amplification Tests, but can later reactivate [83].
In vitro evidence
Thresholds for antimicrobial susceptibility and resistance of C.
trachomatis are not universally standardized, although MICs
>4 mg/ml are often used to characterize therapeutic
failure [84–87]. The lowest concentration of antimicrobial com-
pound needed to inhibit chlamydial formation is between
0.03 and 0.125 mg/ml, whereas the minimum bactericidal con-
centration (MBC; also referred to as the minimum chlamydici-
dal concentration, or MCC) is between 0.06 and 0.5 mg/ml
[88,89]. The published in vitro studies of azithromycin collec-
tively suggest the persistence of high and widespread treatment
efficacy (TABLE 9). One noted exception is the study of six isolates
from three patients who experienced treatment failure in Russia
(2000–2002); four isolates were resistant to azithromycin, dox-
ycycline and ofloxacin at MICs and MBCs >5.12 mg/ml [90].
Not surprisingly, in vitro resistance appears to be more com-
mon in individuals with greater severity of disease or recurrent
disease. A study in the USA during the early 1990s described
decreased susceptibility and emerging resistance to azithromycin
and doxycycline in isolates from women with mucopurulent
cervicitis but not in isolates from women with asymptomatic
infections [91]. Similar observations were reported in 2010 from
India; six of eight isolates with modified susceptibility had been
obtained from recurrently infected individuals, whereas the
remaining two were from nonrecurrently infected patients.
MICs and MBCs for azithromycin were 8 mg/ml for two of
the patients from which the modified susceptibility isolates
were taken. One individual had chronic cervicitis and the other
had pelvic inflammatory disease [92].
Trichomonas vaginalis
In vivo evidence
Trichomonas vaginalis is a protozoal infection which causes cer-
vicitis and nongonococcal urethritis. The WHO recommends
treating pregnant women with T. vaginalis infection after the
first trimester using 2 g metronidazole orally as a single dose,
or 400–500 mg twice daily for 7 days or 300 mg clindamycin
orally twice a day for 7 days [36]. If treatment is imperative dur-
ing the first trimester of pregnancy, the single-dose regimen of
2 g metronidazole orally is recommended [36]. Azithromycin
has not been used directly for prevention or treatment purposes
because T. vaginalis is anaerobic. Nevertheless, azithromycin
has demonstrated protection against T. vaginalis in studies of
mass STI/RTI treatment (TABLES 10 & 11).
In Kenya (1998–2002), 1 g azithromycin or placebo was
given once per month to 466 HIV-negative female sex work-
ers [93]. At the end of the trial, HIV incidence was the same
across treatment groups, the primary endpoint, but the inci-
dence of T. vaginalis was reduced significantly among those
given azithromycin versus placebo (RR: 0.56; 96% CI: 0.40–
0.78; p < 0.001). A similar observation was made in a three-
arm IPTp trial in Malawi (2003–2006) [94]. Pregnant women
received standard IPTp-SP, or monthly IPTp-SP or monthly
IPTp-SP plus 1 g azithromycin during two antenatal visits; the
prevalence of T. vaginalis at delivery was 16.7% (n = 411;
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95% CI: 13.5–20.7%), 15.1% (n = 411; 95% CI: 12.0–
18.9%) and 11.0% (n = 419; 95% CI: 8.3–14.3%), respec-
tively. Thus, women who received azithromycin had 35% (RR:
0.65; 95% CI: 0.46–0.93; p = 0.02) fewer T. vaginalis infec-
tions at delivery compared with monthly recipients of IPTp-SP.
A cluster randomized trial in Uganda (1994–1998) com-
pared the incidence of HIV infections among nonpregnant
adults who received 1 g azithromycin, 250 mg ciprofloxacin
and 2 g metronidazole versus multivitamins plus antihel-
minthics [95]. Although the trial was terminated early for lack
of protection against the primary endpoint, the incidence of
several curable STIs/RTIs was lower in the control group, most
notably T. vaginalis. The cumulative incidence of newly diag-
nosed T. vaginalis infection was 4.8/100 person-years (116/
2,397 person-years) in the intervention group compared with
9.1/100 person-years (182/1,993 person-years) in the control
group (RR: 0.52; 95% CI: 0.35–0.79).
The same combination of antimicrobials was provided to
female sex workers in rural Zimbabwe as a one-time treatment
followed by 3 monthly check-ups [96]. The prevalence of
T. vaginalis was just under 20% at baseline, decreased to
approximately 5% at visit 2, rose to nearly 13% at visit 3 and
lowered again to just over 10%, that is, one-half of the
pretreatment levels.
Bacterial vaginosis
The WHO recommends treating bacterial vaginosis in pregnant
women, preferably after the first trimester, with 200 or 250 mg
metronidazole three-times per day for 7 days, or 5 g metroni-
dazole gel (0.75%) applied intravaginally twice a day for 5 days
or 300 mg clindamycin 300 mg orally twice a day for
7 days [36]. As with T. vaginalis, if treatment is imperative dur-
ing the first trimester of pregnancy, 2 g metronidazole orally is
recommended [36]. Bacterial vaginosis has no single causative
agent, but is thought to result from destabilization of Lactoba-
cillus species (spp.) with secondary colonization of anaerobic
organisms that include Gardnerella vaginalis, Bacteroides spp,
Mobiluncus spp. and Mycoplasma hominis alongside an increase
in vaginal pH [97,98].
In vivo evidence
Our review identified no trials that have attempted to measure
the treatment efficacy of azithromycin alone against bacterial
vaginosis. Only one study in the USA (2002–2005) investi-
gated the use of azithromycin as a partner drug with metroni-
dazole for the treatment of symptomatic bacterial vaginosis.
Nonpregnant women received one of four treatments: 750 mg
metronidazole once per day for 7 days, or metronidazole once
per day for 7 days plus 1 g azithromycin on days 1 and 3, or
metronidazole for 14 days or metronidazole for 14 days plus
azithromycin on days 1 and 3 [99]. No additional benefit of
cure was observed among women who received metronidazole
plus azithromycin compared with metronidazole alone.
Antibiotic treatment for bacterial vaginosis is challenging, in
part, because it is a syndrome that involves multipleT
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microorganisms rather than a single etiological agent. Compa-
rable data from other macrolides suggest potential therapeutic
value for azithromycin against bacterial vaginosis (TABLE 12). Anal-
ysis of azithromycin against the anaerobic and carboxyphilic
bacteria that replace the normal vaginal flora may provide a
better understanding as to the potential role of azithromycin
against bacterial vaginosis.
Discussion
Azithromycin has been used against curable STIs/RTIs for
25 years. It has been an attractive option for preventive and
curative treatment because it is efficacious as a single dose and
offers reasonable tolerability against T. pallidum, N. gonorrhoeae
and C. trachomatis. During the 1990s, and prior to the advent
of antiretroviral therapies for HIV, the management of curable
STIs/RTIs received renewed importance, particularly as trials
showed that treatment of N. gonorrhoeae, C. trachomatis and T.
vaginalis reduced the genital viral load of HIV among men and
women [100–103]. Groups at high risk for transmitting HIV have
since been targeted by treatment campaigns using 1 g azithro-
mycin. Thus, it is not a surprise that changes in azithromycin
sensitivity within high-income settings have often been
observed first among members of high-risk groups. Pregnant
women attending ANC facilities in sub-Saharan Africa do not
have the same risk profile. Thus, on this basis alone, it is less
likely that the use of ABC therapies in IPTp would be a cata-
lyst for the rapid emergence of azithromycin resistance,
although its emergence cannot be ruled out. The potential ben-
efits of ABC therapies may be best viewed through prior expe-
rience with mass drug administration among pregnant women.
In the context of the AIDS epidemic and before the age of
antiretroviral therapies, researchers attempted to prevent mater-
nal-to-child transmission (MTCT) of HIV by providing preg-
nant women in Uganda 1 g azithromycin, in combination with
250 mg ciprofloxacin and 2 g metronidazole [104]. The data
safety monitoring board suspended the trial early for reasons of
futility, despite having cut neonatal deaths by 17% (RR: 0.83;
95% CI: 0.71–0.97), decreased the incidence of low birth-
weight by 32% (RR: 0.68; 95% CI: 0.53–0.86), and reduced
the incidence of preterm delivery by 23% (RR: 0.77; 95% CI:
0.56–1.05). These impressive results were achieved at a time
when neither IPTp-SP nor insecticide treated bed nets for the
control of malaria in pregnancy had been deployed.
If ABC therapies are used in IPTp, then there are several
key factors to consider that are pathogen specific. Regarding
syphilis, 1 g azithromycin should be used alongside 2.4 mu
BPG for three reasons: combination therapy has been shown to
achieve higher rates of cure than either therapy alone [105]; use
of ABC therapy with BPG would likely reduce selection of the
A!G mutation associated with azithromycin and preserve T.
pallidum sensitivity; and only BPG can be expected to cure
congenital infection if the placenta has been invaded by spiro-
chetes [106]. As for N. gonorrhoeae, 1 g azithromycin may be
just above the MIC of fully susceptible strains. Thus, ABC
therapies containing >1 g azithromycin may be preferable from
the standpoint of reducing selection pressure. However, a single
2 g dose may not be well tolerated as 6 in 10 patients reported
self-limiting gastrointestinal discomfort when treated for syphi-
lis infection with such a regimen [42]. The dose could be split
over 2 days to improve tolerability. ABC therapies that contain
2 g azithromycin, either a single- or split-dose, would be pro-
tective against C. trachomatis. Although the data are limited
and the mechanism of action is not understood, ABC therapies
that have 1 g azithromycin may protect against T. vaginalis
based on reports from Malawi among pregnant women [107]
and commercial sex workers in Kenya [93]. It is curious, how-
ever, that T. vaginalis infection during pregnancy is associated
with adverse birth outcomes, but the first-line treatment of 2 g
metronidazole does not always improve birth outcomes. A trial
in Uganda reported that pregnant women treated for T. vagi-
nalis infection were 2.5-times more likely to deliver a low birth-
weight infant than untreated women (RR: 2.49; 95% CI: 1.12–
5.50) [108]. The authors suggest that this may be attributable to
metronidazole exposure. Another trial in the USA reported an
increase in the risk of preterm delivery among pregnant women
exposed to metronidazole for the treatment of asymptomatic tri-
chomoniasis compared with those who were not treated (RR:
1.8; 95% CI: 1.2–2.7) [109]. In contrast to these findings from
high-income settings, data from a multicenter trial in sub-
Saharan Africa indicate that treatment of T. vaginalis infection
using metronidazole does not increase the chances of preterm
birth [110]. Apart from bacterial vaginosis, which is not transmit-
ted through sexual contact, re-infection will remain a risk for
pregnant women and, therefore, providers should continue to
offer education and screening as appropriate.
None of the studies identified in this review indicate that
azithromycin offers preventive or curative effect against bacterial
vaginosis, the most prevalent of curable STIs/RTIs. Antibiotic
therapy has only been shown to reduce the risk of preterm
delivery by one-half (RR: 0.53; 95% CI: 0.34–0.84) among
pregnant women with bacterial vaginosis (Nugent scores 7–10)
or intermediate flora (Nugent scores 4–6) [111]. A Nugent score
of 0–3 is considered normal [112] for which no protection
against adverse birth outcomes has been observed.
Conclusions
ABC therapies are among leading candidates to replace SP for
use in IPTp and may offer important public health benefits by
also reducing the burden of curable STIs/RTIs in pregnancy.
Evidence from nonpregnant adults suggests that ABC therapies
containing 1 g azithromycin may cure maternal T. pallidum
infection. BPG should still be administered with azithromycin
because the combination has been shown to be more efficacious
in nonpregnant adults than either treatment alone. Moreover,
evidence from pregnant women indicates that eradication of
congenital syphilis may require BPG treatment. Neisseria gonor-
rhoeae infection among pregnant women in sub-Saharan Africa,
where strains are likely to be fully sensitive to azithromycin, is
likely to be cured by ABC therapies containing 1 g azithromy-
cin. However, 2 g may be needed to reduce persistent and/or
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recurrent infection, and opportunities for the emergence of
drug resistance. ABC therapy containing 1 g azithromycin
would be curative of C. trachomatis infection, whereas some
protection against T. vaginalis infection could be expected with
the same dose. It remains unknown whether ABC therapies
could offer protection against bacterial vaginosis if administered
during the first half of pregnancy. ABC therapies merit investi-
gation for the use in IPTp given their potential to reduce the
dual burden of malaria and curable STIs/RTIs in pregnancy
and improve maternal, fetal and neonatal health.
Expert commentary
Current strategies for addressing the dual-burden of malaria
and curable STIs/RTIs in pregnancy are suboptimal. In West
Africa, IPTp-SP continues to provide protection against the
effects of malaria infection but, as previously noted, malaria
parasites in East Africa have developed resistance so that IPTp-
SP no longer protects against the malaria attributable fraction
of low birthweight [3]. Some evidence suggests that IPTp-SP
may even be harmful in areas where parasites express the 581G
dhps mutation [4–6]. ABC therapies are likely to be more effica-
cious against malaria parasites in these settings. However, there
is an urgent need for trials of ABC therapies to be conducted
by independent researchers for policymakers to review alongside
the results of trials produced and reported by industry.
In the case of curable STIs/RTIs, the focused ANC package
recommended by the WHO includes screening for syphilis and
the provision of BPG to women who test positive [50]. Screening
would need to continue even if ABC therapies were used in
IPTp. The WHO currently recommends the use of rapid point
of care tests for syphilis in the ANC setting [113]. Using such tests
will expedite case finding and treatment with BPG because
results are available during the same consultation. As for the four
other curable STIs/RTIs of this review, health care providers are
limited to the use of a syndrome-based management algorithm
to diagnose and to treat suspected infections. However, 80% of
gonococcal and 70–75% chlamydial infections in women are
asymptomatic [114] and, therefore, rarely recognized using the
syndromic approach. As a result, the diagnostic algorithm has a
low sensitivity (30–80%) and specificity (40–80%) for N. gonor-
rhoeae and C. trachomatis among pregnant women [115–117]. The
sensitivity for T. vaginalis (54–83%) and bacterial vaginosis (51–
69%) is slightly higher, with moderate specificity for T. vaginalis
(40–54%) and bacterial vaginosis (40–58%) [118]. Given the evi-
dence of this review, ABC therapies used in IPTp could be
expected to mitigate a considerable proportion of this unattended
burden of curable STIs/RTIs.
Much is debated about the utility of a syndrome-based
approach to diagnosing and treating many STIs/RTIs. Its short-
comings, as described above, illuminate a much-needed area for
research. Specifically, more refined definitions of diagnosis need
to be used when characterizing adverse birth outcomes. This is
particularly so with T. vaginalis for which successful treatment
does not necessarily reduce the risk of adverse birth outcomes.
Similarly with bacterial vaginosis, treatment of women who have
Nugent scores of 1–3 has not reduced the incidence of preterm
birth. With both of these infections, is the recommended regi-
men of metronidazole inadequate for radical cure? Is it adminis-
tered too late in pregnancy to alter the course of events? Or are
asymptomatic infections simply much less virulent and, there-
fore, treatment has a marginal effect on selected downstream
measures of the adverse birth outcome? Studies of descriptive epi-
demiology are needed to understand better the extent to which
symptomatic versus asymptomatic curable STIs/RTIs contribute
to adverse birth outcomes. Such descriptive epidemiology, how-
ever, would be incomplete if the prevalence of co-infections were
not also considered. The apparent failure to reduce the incidence
of adverse birth outcomes following treatment for one infection
may be masked by the presence of co-infection(s) that will only
be mitigated with the use of combination therapies and consider-
ation of downstream outcomes. The trial in Uganda that failed
to reduce the incidence of MTCT of HIV is illustrative. HIV
transmission was not interrupted for providing combination
treatment against curable STIs/RTIs, but significant reductions
were observed in the incidence of neonatal deaths by 17% (RR:
0.83; 95% CI: 0.71–0.97) and low birthweight by 32% (RR:
0.68; 95% CI: 0.53–0.86) [104].
Five-year view
Discussion of the future of IPTp needs to be placed in the context
of broader malaria elimination efforts. IPTp-SP has long been
considered a malaria control intervention that can be expected to
protect less against the fraction of low birthweight attributable to
malaria infection as malaria transmission decreases. Recent evi-
dence suggests that IPTp-SP continues to protect against low
birthweight among multigravidae in areas where the prevalence of
malaria parasitemia measured in children is between 7 and 8%,
whereas protection is conferred by IPTp-SP among paucigravidae
until very low levels of transmission [119]. Unpublished results
from a recently completed multicenter trial in West Africa, where
there remain malaria parasites sensitive to SP, indicate that an
approach of intermittent screening and treatment (IST) of malaria
in pregnancy is noninferior to IPTp-SP (Manuscript under
review/personal communication with D. Chandramohan). Thus,
there is an urgent need for clinical trials in an area of high SP
resistance in East Africa, designed to compare ABC therapies
versus IST versus IPTp-SP. ABC therapies, given their action
against malaria and curable STIs/RTIs, would be superior to IST
and IST would be superior to IPTp-SP, potentially paving the
way for adoption of an integrated malaria and curable STI/RTI
control package that employs the use of combination treatment.
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Key issues
• Use of azithromycin-based combination (ABC) therapies may have a transformative effect on maternal, fetal and newborn heath by
mitigating the dual-burden of malaria and curable sexually transmitted infections and reproductive tract infections sexually transmitted
infections and reproductive tract infections (STIs/RTIs) in pregnancy.
• ABC therapies containing two or more grams of azithromycin may be less likely to select for resistance when exposed to Treponema
pallidum, Neisseria gonorrhoeae and potentially, Chlamydia trachomatis.
• In the absence of evidence that azithromycin is curative of congenital syphilis, not simply maternal infection, benzanthine penicillin G
(BPG) will still need to be administered to pregnant women who have a syphilis infection; however, the combination of azithromycin
plus BPG is more efficacious that BPG alone.
• ABC therapies may be preventive of Treponema vaginalis infection during pregnancy, although its impact on birth outcomes needs to
be investigated.
• The most prevalent of all STIs/RTIs, bacterial vaginosis, may or may not be mitigated by the use of ABC therapies.
• Studies of descriptive epidemiology are needed to understand better the extent to which symptomatic versus asymptomatic curable STIs/
RTIs contribute to adverse birth outcomes. There is an urgent need for clinical trials in an area of high sulfadoxine-pyrimethamine resist-
ance in East Africa, designed to compare ABC therapies versus IPTp-SP versus providing IST for malaria in pregnancy during ANC visits.
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